The interesting thing about Bryan Johnson's stomach is not that it is diseased. It is that the disease sat there, in his data, for roughly eleven years, and nobody read it correctly.

Johnson is 48. He is the Silicon Valley entrepreneur behind Project Blueprint, the self-experiment in which he attempts to slow and reverse his own aging, measured obsessively and published in public. On June 30 he posted on X that he had been diagnosed with autoimmune gastritis. His summary was blunt: his stomach, he said, is eating itself. The post was picked up quickly by outlets including the New York Post and LiveNOW from Fox, largely as a curiosity. Man who wants to live to 160 gets incurable illness. Irony noted, move on.

That framing wastes the story. The useful part is the ten-year gap, and what Johnson intends to do about it.

What actually happened

The condition is autoimmune gastritis, sometimes called autoimmune atrophic gastritis. The immune system turns on the parietal cells in the stomach lining, the ones that produce acid and intrinsic factor. Lose the acid and iron absorption suffers. Lose intrinsic factor and vitamin B12 absorption suffers. Left long enough, the lining atrophies, and the clinical literature puts the resulting incidence of gastric cancer at about 0.5% per person-year and type I neuroendocrine tumors at about 2.8% per person-year. It is not a death sentence. It is a slow tax with a tail risk.

Johnson's route to the diagnosis is worth reading closely, because it is a case study in how a signal gets ignored.

He was diagnosed with autoimmune hypothyroidism at 21 and managed it with hormone replacement. For more than a decade after that, his ferritin ran low. Ferritin is the protein that stores iron. His hemoglobin and hematocrit, the numbers doctors actually look at to diagnose anemia, were fine. So the low ferritin got waved through, appointment after appointment.

This is the mechanism that hid it, and Johnson explained it more clearly than most clinicians bother to. Ferritin measures stored iron. Hemoglobin measures circulating iron. The body will drain the reserve to protect the circulating supply, which means you can be genuinely iron deficient while your anemia panel looks unremarkable. The reserve empties quietly. Nothing flags.

He is a vegetarian, which gave everyone an easy explanation to reach for. Low iron in a man who does not eat meat is not a mystery. It is a diet.

The mystery only opened when he replaced his medical team earlier this year and someone ordered a proper investigation. A colonoscopy came back clean, ruling out slow bleeding from polyps or colon cancer. But his team had already booked a bi-directional endoscopy, looking at the upper tract too. Fifteen minutes before the procedure, bloodwork came back showing anti-parietal cell antibodies at 103 units per milliliter, against an upper limit of normal of 20. Biopsies from three regions of the stomach confirmed it: early atrophy, confined to the acid-producing lining, the rest of the stomach still intact.

Caught early, in other words. But only because someone finally looked.

His diagnosis is three diseases, not one

Johnson described the finding as three linked problems rather than one: the iron deficiency, the gastritis driving it, and the autoimmune thyroid disease sitting alongside.

He is right, and this has a name. Thyrogastric syndrome describes the well-documented tendency of autoimmune thyroid disease and autoimmune gastritis to travel together. The relationship is mutually reinforcing in an irritating way. Low iron impairs the conversion of thyroid hormone into its active form. An underactive thyroid impairs how the body uses iron. Each condition makes the other harder to correct, and each supplies a plausible-sounding explanation for the other's symptoms, which is precisely how both stay hidden.

Anyone carrying an autoimmune thyroid diagnosis and stubbornly low ferritin is, on this evidence, worth a second look. That is the practical takeaway buried in a celebrity health story.

He cited a study. The study checks out.

Johnson claimed that in one population with precancerous gastric lesions, around 18% carried the autoimmune antibodies while only about 1% had ever been diagnosed.

That is a real finding, and it is worth naming the source, because he did not. It comes from a 2023 study in the Journal of Clinical Medicine, which tested 256 patients with gastric precancerous lesions and found anti-parietal cell antibody positivity in 18% of cases, against 7% of controls. Three of the 256 had previously been diagnosed with autoimmune gastritis. Three.

So the underdiagnosis claim survives contact with its own citation, which is not something one can always assume in longevity discourse.

The prevalence numbers are shakier. Johnson said the disease affects an estimated 2% to 5% of people. That is at the high end of a genuinely unsettled range. The clinical review puts general-population prevalence between 0.3% and 2.7%, and says outright that the true figure is unclear because studies do not use consistent diagnostic criteria. Some diagnose on biopsy, others on serology alone, others on low B12. A 2026 review in Frontiers in Immunology cites a global estimate of around 3.85%. The honest answer is that nobody knows, and the spread of estimates is itself evidence for Johnson's central complaint. You cannot count a disease you are not looking for.

The cure plan, tier by tier

Here is where Johnson diverges from every other patient with this diagnosis. Standard care for autoimmune gastritis is replacement and surveillance. Replace the iron and B12. Scope the stomach every three to five years, per the MAPS III guidelines, to catch dysplasia or tumors early. Manage, do not solve.

Johnson finds this unacceptable and has published a four-tier plan to attack the disease itself. He was upfront that tiers two through four rest on preclinical evidence at best, and in some cases on therapies that do not exist yet. Graded against the literature:

Tier 1, supportive. Zinc-L-carnosine, and acid replacement with betaine HCl and pepsin under physician supervision. Low risk, thin evidence, unlikely to change the disease course. He has also had his iron deficiency corrected with a 1,000 mg Monoferric infusion, which is simply good care and long overdue.

Tier 2, signaling. Targeting JAK/STAT, GSK-3 and IL-17, plus netazepide to suppress the gastrin drive. The gastrin logic is the strongest thing in the entire plan. When acid production collapses, gastrin rises to compensate, and sustained high gastrin is what drives the enterochromaffin-like cell growth behind type I gastric neuroendocrine tumors. Johnson said he will watch gastrin as his key dial, and that if it climbs, the disease is advancing. That is not biohacker mysticism. That is exactly the mechanism the oncology literature describes.

Tier 3, cellular reset. Induced regulatory T cells, aiming to restore tolerance rather than suppress inflammation. Real research direction, nowhere near the clinic.

Tier 4, frontier. Engineered T-cell therapy, CAR-T or CAAR-T, or AI-designed antibodies built to destroy the specific immune cells attacking his stomach lining.

Tier 4 has a problem nobody is mentioning

The CAR-T excitement is not baseless. Georg Schett's group in Erlangen has produced striking results using CD19-directed CAR-T to wipe out B cells in severe autoimmune disease, with the phase 1/2a CASTLE basket trial reporting drug-free remission in most patients with treatment-refractory lupus, systemic sclerosis and inflammatory myositis, published in Nature Medicine. For patients who had run out of options, that is close to miraculous.

But the field is earlier than the headlines suggest. A survey of the trial landscape found 56 CAR-T trials in autoimmune rheumatic disease, of which roughly 64% were phase I and only four had reached phase II, concentrated almost entirely on lupus. Not one of them is studying autoimmune gastritis.

And there is a mechanistic wrinkle. CD19 CAR-T works by deleting the B-cell compartment, which is a coherent strategy when pathogenic autoantibodies are doing the damage. In autoimmune gastritis, the destruction of parietal cells is generally understood to be driven by autoreactive T cells targeting the gastric H+/K+ ATPase, with the anti-parietal cell antibodies serving largely as a marker of the process rather than its engine. Delete the B cells and you may erase the diagnostic signal while leaving the arsonists in the building.

That does not kill the idea. CAAR-T, the chimeric autoantibody receptor approach, is designed to be more surgical, and antigen-specific tolerance work is aimed at the T-cell problem directly. But it means the leap from lupus remission to a cured stomach is longer than an inspiring post makes it sound, and the difference is not a funding gap. It is a biology gap.

Johnson, to his credit, said as much. He called tiers two through four investigational and invited researchers working on antigen-specific tolerance, regulatory T cells and CAAR-T to get in touch. That is a fair use of a large platform.

What the case is actually worth

There is an obvious joke here about the man optimizing for immortality being unable to optimize his own stomach, and it has been made everywhere, and it is not very good.

The more uncomfortable observation is the one Johnson keeps returning to. He is among the most comprehensively measured humans on the planet, running a protocol that reportedly costs him around a million dollars a year, and the disease still hid inside him for a decade. Not because the data was missing. The low ferritin was right there, year after year. It hid because the system was built to react to anemia, and he did not have anemia yet. He had an empty reserve and a normal-looking chart.

That is not a failure of measurement. It is a failure of interpretation, and no amount of extra sensors fixes it.

Which leaves a genuinely useful question for anyone who is not a millionaire with a private medical team. If you have persistently low ferritin, normal hemoglobin, and a thyroid condition, has anyone actually looked at your stomach? The clinical guidance supports asking. The disease is quiet, it is treatable when caught early, and the cost of catching it late is measured in tumors.

Johnson may or may not cure himself. The odds are not good, and he knows it. But if his post causes a few thousand people to point at an old blood panel and ask an inconvenient question, that will have been worth considerably more than the protocol.

Further reading